Per tablet contains: Mefenamic Acid 500 mg.
Per capsule contains: Mefenamic Acid 500 mg and 250 mg.
Per 5 mL (1 teaspoonful contains): Mefenamic Acid 50 mg.
Pharmacology: Mefenamic Acid is a unique analgesic with dual action. It inhibits prostaglandin synthesis and blocks its action at the receptor site.
Mefenamic Acid is indicated in the relief of mild to moderately severe somatic and neuritic pains such as headache, migraine, traumatic pain, postpartum pain, postoperative pain, dental pain and pain conditions: dysmenorrheal, hemorralgia, accompanied by spasm or hypogastric pain.
Tab 500 mg: One tablet three times a day preferably taken with food. Or as prescribed by the physician.
Cap 250 mg & 500 mg: One to two capsules three times a day or as prescribed by the physician.
50 mg/5 mL suspension: Children: 6 months to under 2 years: 5 mL (1 teaspoonful).
2 years to under 5 years: 10 mL (2 teaspoonfuls).
5 years to under 9 years: 15 mL (3 teaspoonfuls).
9 years to 12 years: 20 mL (4 teaspoonfuls) repeated as necessary up to three times daily or as prescribed by the physician. Should not be given for longer than 7 days at a time.
Although doses up to 6000 mg/day have been given no specific information is available on the management of acute massive overdosage.
Should accident overdosage occur, the stomach should be emptied by inducing emesis or by careful gastric lavage followed by the administration of activated charcoal.
Mefenamic Acid is contraindicated in inflammatory bowel disease and in patients suffering from peptic and intestinal ulceration and in patients with renal or hepatic impairment.
Absolute contraindications: Not be given to those patients who have history of: Stroke: cerebrovascular accident, CVA; Heart attack: Myocardial infarction, MI; Coronary artery bypass graft: CABG; Uncontrolled hypertension; Congestive heart failure (CHF) NYHA II-IV.
Contraindication in patients with history of hypersensitivity to ASA or any other NSAIDs.
NSAIDs are contraindicated in patients with previous or active peptic ulceration.
Use with caution in patients with cardiac, liver and renal disease. Dose adjustment like using the lowest effective dose and monitoring of renal and liver functions should be instituted.
In patients suffering from dehydration and renal disease, particularly the elderly, concurrent therapy with other plasma protein binding drugs may decessitate a modification in dosage. In the case of anticoagulants, the dose of the anticoagulant may need to be reduced. The safety of Mefenamic Acid in pregnancy and in children under 14 years of age has not been established.
Pregnancy: Congenital abnormalities have been reported in association with NSAID administration in man; however, these are low in frequency and do not appear to follow any discernible pattern. In view of the known effects of NSAIDs on the fetal cardiovascular system (risk of closure of the ductus arteriosus), use in the last trimester of pregnancy is contraindicated. The onset of labor may be delayed and the duration increased with an increased bleeding tendency in both mother and child. NSAIDs should not be used during first trimesters of pregnancy or labor unless the potential benefit to the patient outweighs the potential risk to the fetus.
Lactation: Trace amounts of mefenamic acid may be present in breast milk and transmitted to the nursing infant. Therefore, mefenamic acid should not be taken by nursing mothers.
Gastrointestinal discomfort, diarrhea or gas constipation, nausea, vomiting, drowsiness and dizziness have been observed. Signs of hemolytic anemia should be watched in cases when the drug is taken on prolonged period of time. As in all inhibitors of prostaglandin synthesis, Mefenamic Acid can affect platelet function. In large doses the drug may induce Grand Mal convulsions hence it is suggested to avoid this in epileptics.
Concomitant therapy with other plasma protein binding drugs may necessitate a modification of dosage. In the case of anticoagulants frequent monitoring of prothrombin time is necessary.
Store at temperatures not exceeding 30°C.
M01AG01 - mefenamic acid ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.
250-mg cap:Non-Rx;500-mg cap/susp:Rx
Ponser cap 250 mg
100's (P300/pack)
Ponser cap 500 mg
100's (P500/box)
Ponser oral susp 50 mg/5 mL
60 mL x 1's (P80/bottle)
Ponser tab 500 mg
100's (P450/pack)
Sign Out
